Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says. Watch here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksWHIreland Regulatory News (WHI)

  • This share is currently suspended. It was suspended at a price of 3.75
  • There is currently no data for WHI

Senior Appointments

30 Mar 2010 12:37

RNS Number : 4219J
W.H. Ireland Group PLC
30 March 2010
 



WH Ireland Group Plc

 

Appointment of New Heads of Institutional Sales/Trading and Corporate Finance

 

WH Ireland Group plc (AIM:WHI), the financial services group, is delighted to announce two senior appointments to lead its Institutional Sales/Trading and Corporate Finance operations. Both will be joining in the week commencing 12 April 2010.

 

Russell Hooper joins as Head of Institutional Sales/Trading and will be responsible for coordinating the Group's institutional stockbroking business. Previously, Russell has been Head of European Institutional Client Sales Trading and also Head of Pan European Hedge Fund Sales Trading at Merrill Lynch where he spent 15 years in the Institutional Equities division. He graduated in Materials Engineering from Cardiff University. His interests include cricket, rugby (Welsh) and cycling.

 

Chris Fielding joins as Head of Corporate Finance, bringing with him over 20 years' experience in corporate finance as a small/mid cap specialist. Since 2005, Chris has worked at Arden Partners, having previously spent eleven years at Hoare Govett, where he was a director of Corporate Finance. He qualified as a chartered accountant with Price Waterhouse. Chris will be based in the Group's London office and will lead the continued expansion of the corporate finance business. Chris' interests and hobbies include rugby (English), skiing, classic cars, travel and walking.

 

The WH Ireland team already has significant depth of experience and strong regional coverage through John Wakefield (Bristol), Dan Bate (Manchester), James Joyce (London) and their respective teams, supported by the Group's award-winning research team, based in Leeds, headed by Matthew Davis. In line with the Group's strategy, these appointments will further enhance WH Ireland's institutional sales and corporate finance offering.

 

Commenting on the appointments, Richard Ford (CEO) said:

 

"We are delighted to have secured the services of two top calibre individuals both of whom bring substantial skill and experience to the firm. These appointments come at a time when we are seeing a significant uplift in client demand for our corporate stockbroking services where we are looking to build our already strong position in the market. Russell and Chris will continue to drive our business forward and complement our existing Securities business both in London and through our principal regional offices in Manchester, Leeds, Birmingham and Bristol."

 

John Wakefield commented:

 

"The two appointments continue the work already in place to address the aspirations of our corporate client base to gain wider access to sources of capital and to benefit from best of breed advice in our core small/mid cap market."

 

Matthew Davis (Head of Institutional Research) said of the appointments:

 

"Both Chris and Russell bring significant experience, further enhancing WH Ireland's distribution capability, both corporately and institutionally."

 

30 March 2010

 

Enquiries:

 

WH Ireland Tel: 020 7220 1666

Richard Ford

 

Biddicks (Financial PR to WH Ireland) Tel: 020 7448 1000

Zoe Biddick

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NRAFMGFFMGDGGZM
Date   Source Headline
29th Mar 20127:00 amRNSNotice of AGM/Annual Report & Accounts
23rd Mar 20127:00 amRNSPreliminary Results
15th Mar 20128:27 amRNSHolding(s) in Company
7th Mar 20127:00 amRNSWH Ireland strengthens corporate broking team
29th Feb 20127:00 amRNSAcquisition of Client List from Pritchard
18th Jan 20124:24 pmRNSTreasury Stock and Total Voting Rights
1st Dec 20115:43 pmRNSDirector's Dealing
30th Nov 20119:11 amRNSTotal Voting Rights
28th Nov 201111:13 amRNSDirector's Dealing
28th Nov 20117:00 amRNSDirector dealing(s)
7th Nov 20114:38 pmRNSHolding(s) in Company
2nd Nov 20115:19 pmRNSEmployee share plans, director dealing(s) and TVR
11th Oct 20117:00 amRNSChange of Registered Office
31st Aug 20117:00 amRNSTotal Voting Rights
18th Aug 20114:11 pmRNSDirector's Dealing
5th Aug 20112:08 pmRNSAdditional Listing and Total Voting Rights
28th Jul 20113:14 pmRNSDirector/PDMR Shareholding
26th Jul 20118:18 amRNSHolding(s) in Company
21st Jul 20119:40 amRNSHolding(s) in Company
18th Jul 201110:35 amRNSInterim Report - Replacement
18th Jul 20119:00 amRNSInterim Report
18th Jul 20117:00 amRNSHalf Year Results
20th May 20119:14 amRNSDisposal
21st Apr 201111:00 amRNSResult of AGM
21st Apr 20117:00 amRNSAGM Statement
12th Apr 20113:11 pmRNSHolding(s) in Company
12th Apr 20111:28 pmRNSDirector/PDMR Shareholding
5th Apr 20118:01 amRNSDirector/PDMR Shareholding
28th Mar 20113:25 pmRNSHolding(s) in Company
10th Mar 201110:39 amRNSDirector/PDMR Shareholding
2nd Mar 201110:44 amRNSNotice of AGM
28th Feb 20117:00 amRNSTotal Voting Rights and Director Shareholdings
28th Feb 20117:00 amRNSFinal Results
23rd Feb 20117:00 amRNSDirector/PDMR Shareholding
7th Feb 20115:13 pmRNSHolding(s) in Company
31st Jan 20117:30 amRNSDirectorate Change
29th Nov 20104:20 pmRNSHolding(s) in Company
18th Nov 20103:52 pmRNSHolding(s) in Company
17th Nov 20109:57 amRNSHolding(s) in Company
12th Nov 20107:45 amRNSChange of Adviser
1st Nov 20107:00 amRNSBoard Appointment
18th Oct 201011:04 amRNSHolding(s) in Company
20th Sep 20102:00 pmRNSUpdate on appointment of new CEO
16th Sep 20109:26 amRNSHolding(s) in Company
14th Sep 20105:34 pmRNSHolding(s) in Company
9th Aug 201011:59 amRNSInterim Report posted on website
28th Jul 201012:31 pmRNSHolding(s) in Company
26th Jul 201010:20 amRNSDirector/PDMR Shareholding
23rd Jul 20107:00 amRNSHalf Year Results
23rd Jul 20107:00 amRNSAppointment of New CEO & Board Changes

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.